Cross-immunity against SARS-COV-2 variants of concern in naturally infected critically ill COVID-19 patients.

ACE2, angiotensin-converting enzyme AUC, area-under-the-curve Adaptive immunity Antibodies COPD, chronic obstructive pulmonary disease COVID-19 COVID-19, coronavirus disease 2019 ICU, intensive care unit IQR, interquartile range Intensive care units MFI, median fluorescence intensity MODS, multi-organ dysfunction score Neutralizing P/F, arterial partial pressure to inspired oxygen RBD, receptor binding domain REB, research ethics board ROC, receiver operating characteristic SARS-CoV-2 SARS-CoV-2 alpha variant SARS-CoV-2 beta variant SARS-CoV-2 delta variant SARS-CoV-2 gamma variant SOFA, sequential organ failure assessment VOC, variants of concern VTE, venous thromboembolism WT, wild-type

Journal

Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560

Informations de publication

Date de publication:
Jan 2023
Historique:
received: 12 07 2022
revised: 21 12 2022
accepted: 23 12 2022
pubmed: 4 1 2023
medline: 4 1 2023
entrez: 3 1 2023
Statut: ppublish

Résumé

Critically ill patients infected with SARS-CoV-2 display adaptive immunity, but it is unknown if they develop cross-reactivity to variants of concern (VOCs). We profiled cross-immunity against SARS-CoV-2 VOCs in naturally infected, non-vaccinated, critically ill COVID-19 patients. Wave-1 patients (wild-type infection) were similar in demographics to Wave-3 patients (wild-type/alpha infection), but Wave-3 patients had higher illness severity. Wave-1 patients developed increasing neutralizing antibodies to all variants, as did patients during Wave-3. Wave-3 patients, when compared to Wave-1, developed more robust antibody responses, particularly for wild-type, alpha, beta and delta variants. Within Wave-3, neutralizing antibodies were significantly less to beta and gamma VOCs, as compared to wild-type, alpha and delta. Patients previously diagnosed with cancer or chronic obstructive pulmonary disease had significantly fewer neutralizing antibodies. Naturally infected ICU patients developed adaptive responses to all VOCs, with greater responses in those patients more likely to be infected with the alpha variant, versus wild-type.

Identifiants

DOI: 10.1016/j.heliyon.2022.e12704 PMID: 36594041 PMC: PMC9797417
pubmed: 36594041
doi: 10.1016/j.heliyon.2022.e12704
pii: S2405-8440(22)03992-5
pmc: PMC9797417
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e12704

Informations de copyright

© 2022 The Authors.

Déclaration de conflit d'intérêts

Some authors are employees of Thermo Fisher Scientific Inc. who manufacture and distribute the anti-SARS-CoV-2 immunoglobulin assays as research use only reagents.

Auteurs

Douglas D Fraser (DD)

Lawson Health Research Institute, London, ON, N6C 2R5, Canada.
Pediatrics, Western University, London, ON, N6A 3K7, Canada.
Clinical Neurological Sciences, Western University, London, ON, N6A 3K7, Canada.
Physiology & Pharmacology, Western University, London, ON, N6A 3K7, Canada.

Maitray A Patel (MA)

Epidemiology, Western University, London, ON, N6A 3K7, Canada.

Logan R Van Nynatten (LR)

Medicine, Western University, London, ON, N6A 3K7, Canada.

Claudio Martin (C)

Lawson Health Research Institute, London, ON, N6C 2R5, Canada.
Medicine, Western University, London, ON, N6A 3K7, Canada.

Shannon L Seney (SL)

Lawson Health Research Institute, London, ON, N6C 2R5, Canada.

Michael R Miller (MR)

Lawson Health Research Institute, London, ON, N6C 2R5, Canada.
Pediatrics, Western University, London, ON, N6A 3K7, Canada.

Mark Daley (M)

Epidemiology, Western University, London, ON, N6A 3K7, Canada.

Marat Slessarev (M)

Lawson Health Research Institute, London, ON, N6C 2R5, Canada.
Medicine, Western University, London, ON, N6A 3K7, Canada.

Gediminas Cepinskas (G)

Lawson Health Research Institute, London, ON, N6C 2R5, Canada.
Medical Biophysics, Western University, London, ON, N6A 3K7, Canada.

Ganeem K Juneja (GK)

Medicine, McMaster University, Hamilton, ON, L8S 4L8, Canada.
Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, L8L 2X2, Canada.

Vanessa Sabourin (V)

Medicine, McMaster University, Hamilton, ON, L8S 4L8, Canada.
Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, L8L 2X2, Canada.

Alison Fox-Robichaud (A)

Medicine, McMaster University, Hamilton, ON, L8S 4L8, Canada.
Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, L8L 2X2, Canada.

Calvin H Yeh (CH)

Medicine, McMaster University, Hamilton, ON, L8S 4L8, Canada.
Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, L8L 2X2, Canada.

Paul Y Kim (PY)

Medicine, McMaster University, Hamilton, ON, L8S 4L8, Canada.
Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, L8L 2X2, Canada.

Sigrun Badrnya (S)

Thermo Fisher Scientific, Vienna, Austria.

Susanne Oehler (S)

Thermo Fisher Scientific, Vienna, Austria.

Markus Miholits (M)

Thermo Fisher Scientific, Vienna, Austria.

Brian Webb (B)

Thermo Fisher Scientific, Rockford, IL, USA.

Classifications MeSH